1 227

Cited 7 times in

Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.

 Jae Yun Lim  ;  Jae Yong Cho  ;  Kyung Jin Oh  ;  Seung Ho Choi  ;  Sang In Lee  ;  Hei-Cheul Jeung 
 CHEMOTHERAPY, Vol.55(4) : 200-206, 2009 
Journal Title
Issue Date
Adenocarcinoma/drug therapy* ; Adenocarcinoma/secondary ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Female ; Fluorouracil/administration & dosage* ; Fluorouracil/adverse effects ; Fluorouracil/therapeutic use ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Organoplatinum Compounds/administration & dosage* ; Organoplatinum Compounds/adverse effects ; Organoplatinum Compounds/therapeutic use ; Stomach Neoplasms/drug therapy* ; Stomach Neoplasms/pathology ; Treatment Outcome
Combination treatment ; FOLFOX ; Gastric cancer ; Oxaliplatin
BACKGROUND: The aim of this clinical study was to evaluate the efficacy of combination chemotherapy of oxaliplatin, leucovorin and continuous-infusion 5-fluorouracil (5-FU) for advanced gastric cancer. METHODS: Patients with previously untreated gastric cancer with measurable disease received oxaliplatin (100 mg/m(2), day 1), followed by leucovorin (100 mg/m(2), day 1) and 5-FU (2,400 mg/m(2), days 1-2), which was repeated every 2 weeks. The primary endpoint was overall response rate (ORR) and secondary endpoints were progression-free survival (PFS), overall survival (OS) and toxicity. RESULTS: Forty-eight patients were enrolled, and 45 were evaluable for response. A total of 320 cycles of chemotherapy were administered (median 6 cycles per patient). One complete response (2.1%) and 19 partial responses (39.6%) were noted, resulting in an ORR of 41.7% (95% confidence interval, CI: 27.7-55.6%) by intent-to-treat analysis. With a median follow-up duration of 22 months, the median PFS was 5.3 (95% CI: 2.8-7.8) months and the median OS was 13.6 (95% CI: 9.3-17.9) months. There was 1 treatment-related death, and the most common grade 3/4 toxicity was neutropenia (36.1%). Three patients discontinued treatment because of serum creatinine elevation. CONCLUSION: This study reaffirms the efficacy of oxaliplatin in advanced gastric cancer, but its dose of 100 mg/m(2) remains to be reconsidered in Korean patients.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Sang In(이상인)
Lim, Jae Yun(임재윤)
Jeung, Hei Cheul(정희철) ORCID logo https://orcid.org/0000-0003-0952-3679
Cho, Jae Yong(조재용) ORCID logo https://orcid.org/0000-0002-0926-1819
Choi, Seung Ho(최승호) ORCID logo https://orcid.org/0000-0002-9872-3594
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.